Interpretable correlation descriptors for quantitativestructure-activity relationships

Journal of Cheminformatics

Volumn 1, Issue 1, 2009, Pages

  Spowage, Benson M ^a   Bruce, Craig L ^a,b   Hirst, Jonathan D ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76749120557     PISSN: None     EISSN: 17582946     Source Type: Journal    
DOI: 10.1186/1758-2946-1-22     Document Type: Article

References (58)

1. MA Johnson GM Maggiora, Concepts and applications of molecular similarity New York, NY, USA: John Wiley and Sons 1990
2. On the interpretation and interpretability of quantitative structure-activity relationships. R Guha, J Comput Aided Mol Des 2008 22 857 871
3. QSAR - how good is it in practice? Comparison of descriptor sets on an unbiased cross section of corporate data sets. P Gedeck B Rohde C Bartels, J Chem Inf Model 2006 46 1924 1936
4. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. RD Brown YC Martin, J Chem Inf Comput Sci 1996 36 572 584
5. A quantitative approach to biological structure-activity relationships. C Hansch, Acct Chem Res 1969 2 232 239
6. Soft modelling: The basic design and some extension. H Wold, Systems under indirect observations: Causality, structure, prediction Amsterdam: North Holland, Joerskog KG, Wold H, 1982 1 54
7. On the physical interpretation of QSAR models. DT Stanton, J Chem Inf Comput Sci 2003 43 1423 1433
8. Development of QSAR models to predict and interpret the biological activity of artemisinin analogues. R Guha PC Jurs, J Chem Inf Comput Sci 2004 44 1440 1449
9. TMACC: Interpretable correlation descriptors for quantitative structure-activity relationships. JL Melville JD Hirst, J Chem Inf Model 2007 47 626 634
10. Grid-independent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors. M Pastor G Cruciani I Mclay S Pickett S Clementi, J Med Chem 2000 43 3233 3243
11. The autocorrelation of a topological structure: A new molecular descriptor. G Moreau P Broto, Nouv J Chim 1980 4 359 360
12. Beware of q(2)! A Golbraikh A Tropsha, J Mol Graphics Modell 2002 20 269 276
13. Assessing model fit by cross-validation. DM Hawkins SC Basak D Mills, J Chem Inf Comput Sci 2003 43 579 586
14. The problem of overfitting. DM Hawkins, J Chem Inf Comput Sci 2004 44 1 12
15. Estimating the uncertainty in estimates of root mean square error of prediction: Application to determining the size of an adequate test set in multivariate calibration. NKM Faber, Chemom Intell Lab Syst 1999 49 79 89
16. The trouble with QSAR (or how I learned to stop worrying and embrace fallacy). SR Johnson, J Chem Inf Model 2008 48 25 26
17. Comparison of methods for modelling quantitative structure-activity relationships. JJ Sutherland LA O'Brein DF Weaver, J Med Chem 2004 47 5541 5554
18. 3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors - a comparison of CoMFA models based on deduced and experimentally determined active-site geometries. SA DePriest D Mayer CB Naylor GR Marshall, J Am Chem Soc 1993 115 5372 5384
19. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. J Gasteiger M Marsili, Tetrahedron 1980 36 3219 3228
20. Adme evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach. TJ Hou K Xia W Zhang XJ Xu, J Chem Inf Comput Sci 2004 44 266 275
21. Prediction of physicochemical parameters by atomic contributions. SA Wildman GM Crippen, J Chem Inf Comput Sci 1999 39 868 873
22. Crystal structure of the human ace-lisinopril complex. R Natesh SL Schwager ED Sturrock KR Acharya, Nature 2003 421 551 554
23. Angiotensin-converting enzyme inhibition: A landmark advance in treatment for cardiovascular disease. JS Borer, Eur Heart J Suppl 2007 9 2 E9
24. A new class of angiotensin-converting enzyme-inhibitors. AA Patchett E Harris EW Tristram MJ Wyvratt MT Wu D Taub ER Peterson TJ Ikeler J Tenbroeke LG Payne DL Ondeyka ED Thorsett WJ Greenlee NS Lohr RD Hoffsommer H Joshua WV Ruyle JW Rothrock SD Aster AL Maycock FM Robinson R Hirschmann CS Sweet EH Ulm DM Gross TC Vassil CA Stone, Nature 1980 288 280 283
25. Angiotensin-converting enzyme-inhibitors - biochemical properties and biological actions. MA Ondetti DW Cushman, CRC Critical Reviews in Biochemistry 1984 16 381 411
26. Spectrophotometric assay and properties of angiotensin-converting enzyme of rabbit lung. DW Cushman HS Cheung, Biochem Pharmacol 1971 20 1637 1648
27. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. S Fuchs HD Xiao C Hubert A Michaud DJ Campbell JW Adams MR Capecchi P Corvol KE Bernstein, Hypertension 2008 51 267 274
28. The 2 homologous domains of human angiotensin-I-converting enzyme are both catalytically active. L Wei F AlhencGelas P Corvol E Clauser, J Biol Chem 1991 266 9002 9008
29. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. HR Corradi SL Schwager AT Nchinda ED Sturrock KR Acharya, J Mol Biol 2006 357 964 974
30. A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies. D Mayer CB Naylor I Motoc GR Marshall, J Comput Aided Mol Des 1987 1 3 16
31. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. R Natesh SLU Schwager HR Evans ED Sturrock KR Acharya, Biochemistry 2004 43 8718 8724
32. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors. AG Tzakos IP Gerothanassis, Chem Biochem 2005 6 1089 1103
33. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. HR Corradi I Chitapi BT Sewell D Georgiadis V Dive ED Sturrock KR Acharya, Biochemistry 2007 46 5473 5478
34. Angiotensin I-converting enzyme transition state stabilization by His(1089): Evidence for a catalytic mechansim distinct from other gluzincin metalloproteinases. M Fernandez X Liu MS Wouters S Heyberger A Husain, J Biol Chem 2001 276 4998 5004
35. Phosphinic peptides as zinc metalloproteinase inhibitors. V Dive D Georgiadis M Matziari A Makaritis F Beau P Cuniasse A Yiotakis, Cell Mol Life Sci 2004 61 2010 2019
36. Selective angiotensin-converting enzyme c-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. JHM van Esch B Tom V Dive WW Batenburg D Georgiadis A Yiotakis JMG van Gool RJA de Bruijn R de Vries AHJ Danser, Hypertension 2005 45 120 125
37. Acute angiotensin-converting enzyme inhibition increases the plasma level of the antural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. M Azizi A Rousseau E Ezan TT Guyene S Michelet JM Grognet M Lenfant P Corvol J Menard, J Clin Invest 1996 97 839 844
38. New insights into the role of angiotensin-converting enzyme obtained from the analysis of genetically modified mice. XZ Shen HD Xiao P Li CX Lin S Billet D Okwan-Duodu JW Adams EA Bernstein Y Xu S Fuchs KE Bernstein, Journal of Molecular Medicine-Jmm 2008 86 679 684
39. Folate and antifolate pharmacology. B Kamen, Semin Oncol 1997 24 30 S18
40. Dihydrofolate-reductase as a therapeutic target. BI Schweitzer AP Dicker JR Bertino, FASEB J 1990 4 2441 2452
41. DNA and RNA synthesis: Antifolates. IM Kompis K Islam RL Then, Chem Rev 2005 105 593 620
42. Pemetrexed disodium, a novel antifolate with multiple targets. NJ Curtin AN Hughes, Lancet Oncol 2001 2 298 306
43. Potent invitro and invivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. CJ Allegra JA Kovacs JC Drake JC Swan BA Chabner H Masur, J Clin Invest 1987 79 478 482
44. Recent advances in the management of AIDS-related opportunistic infections. HC Lane BE Laughon J Falloon JA Kovacs RT Davey MA Polis H Masur, Ann Intern Med 1994 120 945 955
45. Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme. YH Wang JA Bruenn SF Queener V Cody, Antimicrob Agents Chemother 2001 45 2517 2523
46. Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 angstrom and 1.05 angstrom resolution. AE Klon A Heroux LJ Ross V Pathak CA Johnson JR Piper DW Borhani, J Mol Biol 2002 320 677 693
47. Comparison of ternary complexes of pneumocystis carinii and wild-type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate. V Cody N Galitsky JR Luft W Pangborn A Gangjee R Devraj SF Queener RL Blakley, Acta Crystallographica Section D-Biological Crystallography 1997 53 638 649
48. Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling. R Pignatello S Guccione S Forte C Di Giacomo V Sorrenti L Vicari GU Barretta F Balzano G Puglisi, Bioorg Med Chem 2004 12 2951 2964
49. Inhibition of mammalian dihydrofolate-reductase by selected 2,4-diaminoquinazolines and related compounds. WE Richter JJ McCormac, J Med Chem 1974 17 943 947
50. Crystal-structure of human dihydrofolate-reductase complexed with folate. C Oefner A Darcy FK Winkler, Eur J Biochem 1988 174 377 385
51. Solution structure of human dihydrofolate reductase in its complex with trimethoprim and NADPH. NV Kovalevskaya YD Smurnyy VI Polshakov B Birdsall AF Bradbury T Frenkiel J Feeney, J Biomol NMR 2005 33 69 72
52. Crystal-structures of escherichia-coli and lactobacillus-casei dihydrofolate-reductase refined at 1.7 Å resolution.1. General features and binding of methotrexate. JT Bolin DJ Filman DA Matthews RC Hamlin J Kraut, J Biol Chem 1982 257 22 13650 13662
53. Structure-based design and synthesis of lipophilic 2,4-diamino-6- substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. A Gangjee AP Vidwans A Vasudevan SF Queener RL Kisliuk V Cody RM Li N Galitsky JR Luft S Pangborn, J Med Chem 1998 41 3426 3434
54. Analysis of quinazoline and pyrido[2,3-d]-pyrimidine n9-c10 reversed-bridge antifolates in complex with NADP(+) and pneumocystis carinii dihydrofolate reductase. V Cody N Galitsky JR Luft W Pangborn SF Queener A Gangjee, Acta Crystallographica Section D-Biological Crystallography 2002 58 1393 1399
55. Neutron diffraction studies of escherichia coli dihydrofolate reductase complexed with methotrexate. B Bennett P Langan L Coates M Mustyakimov B Schoenborn EE Howell C Dealwis, Proc Natl Acad Sci USA 2006 103 18493 18498
56. Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido [2,3-d]pyrimidines as dihydrofolate reductase inhibitors. A Gangjee O Adair SF Queener, Bioorg Med Chem 2001 9 2929 2935
57. QSAR modeling using chirality descriptors derived from molecular topology. A Golbraikh A Tropsha, J Chem Inf Comput Sci 2003 43 144 154
58. Partial charge calculation method affects CoMFA QSAR prediction accuracy. RR Mittal L Harris RA McKinnon MJ Sorich, J Chem Inf Model 2009 49 704 709